Sun Pharma lines up USD 100 mn to commercialise niche products this fiscal

Sun Pharmaceutical Industries plans a USD 100 million investment to commercialize innovative products this fiscal year, focusing on its specialty business. The company will launch Unloxcyt and Leqselvi, while seeking a partner for MM-II development. Sun Pharma anticipates mid-to-high single-digit consolidated topline growth for FY26 and expects R&D spending to be 6-8% of sales.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/2firuNT
via IFTTT